BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status (Q38120669)

29 August 2017

title

BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status (English)

1 reference

29 August 2017

0 references

Genevieve Evin

1 reference

29 August 2017

Christopher Hince

series ordinal

1 reference

29 August 2017

publication date

1 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

1 reference

29 August 2017

1 reference

29 August 2017

page(s)

755-764

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

29 August 2017

1 reference

Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Amyloid plaque core protein in Alzheimer disease and Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Alzheimer's disease: the amyloid cascade hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Epidemiology of neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Testing times for the "amyloid cascade hypothesis".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

The Pathogenesis of Alzheimer′s Disease: A Reevaluation of the “Amyloid Cascade Hypothesis”

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Twenty years of Alzheimer's disease-causing mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

All in the Family: How the APPs Regulate Neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Interactome of the amyloid precursor protein APP in brain reveals a protein network involved in synaptic vesicle turnover and a close association with Synaptotagmin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

The secretases: enzymes with therapeutic potential in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Processing of beta-secretase by furin and other members of the proprotein convertase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Amyloid precursor protein (APP) A673T mutation in the elderly Finnish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

BACE1 structure and function in health and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Purification and cloning of amyloid precursor protein beta-secretase from human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Characterization of Alzheimer's beta -secretase protein BACE. A pepsin family member with unusual properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Processing amyloid precursor protein at the beta-site requires proper orientation to be accessed by BACE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

The transmembrane domain of the Alzheimer's beta-secretase (BACE1) determines its late Golgi localization and access to beta -amyloid precursor protein (APP) substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Maturation and pro-peptide cleavage of beta-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's beta -secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Identification and biology of β-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

GGA proteins mediate the recycling pathway of memapsin 2 (BACE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Memapsin 2 (beta-secretase) cytosolic domain binds to the VHS domains of GGA1 and GGA2: implications on the endocytosis mechanism of memapsin 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Demonstration of BACE (beta-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

BACE1 protein endocytosis and trafficking are differentially regulated by ubiquitination at lysine 501 and the Di-leucine motif in the carboxyl terminus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Ubiquitin regulates GGA3-mediated degradation of BACE1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Human BACE forms dimers and colocalizes with APP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Dimerization of beta-site beta-amyloid precursor protein-cleaving enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

BACE1 dependent neuregulin processing: review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Increased beta-Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Bace1 processing of NRG1 type III produces a myelin-inducing signal but is not essential for the stimulation of myelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Amyloid-β production: major link between oxidative stress and BACE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and β-amyloid production in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Beta-secretase activity increases with aging in human, monkey, and mouse brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Mild oxidative stress induces redistribution of BACE1 in non-apoptotic conditions and promotes the amyloidogenic processing of Alzheimer's disease amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

BACE: Therapeutic target and potential biomarker for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

BACE Inhibitors as Potential Drugs for the Treatment of Alzheimers Disease: Focus on Bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Acyl guanidine inhibitors of β-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid- and solution-phase library synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Developing β-secretase inhibitors for treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Discovery of pyrrolidine-based β-secretase inhibitors: lead advancement through conformational design for maintenance of ligand binding efficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Identification of a small molecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Identification of a small molecule beta-secretase inhibitor that binds without catalytic aspartate engagement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Structure- and property-based design of aminooxazoline xanthenes as selective, orally efficacious, and CNS penetrable BACE inhibitors for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Control of peripheral nerve myelination by the beta-secretase BACE1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Dual cleavage of neuregulin 1 type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Bace1 modulates myelination in the central and peripheral nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Neuregulin 1 in neural development, synaptic plasticity and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Disrupted-in-Schizophrenia-1 expression is regulated by beta-site amyloid precursor protein cleaving enzyme-1-neuregulin cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

BACE1 and presenilin/γ-secretase regulate proteolytic processing of KCNE1 and 2, auxiliary subunits of voltage-gated potassium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Identification of beta-secretase (BACE1) substrates using quantitative proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

β-Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

BACE1 deficiency causes altered neuronal activity and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

BACE1-/- mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Sodium channel cleavage is associated with aberrant neuronal activity and cognitive deficits in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

BACE1 Suppression by RNA Interference in Primary Cortical Neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Lentivirus-expressed siRNA vectors against Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Amyloid-beta in Alzheimer Disease: The Null versus the Alternate Hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

Decreased expression of GGA3 Protein in Alzheimer's disease frontal cortex and increased co-distribution of BACE with the amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0099-3

BACE1 in central nervous system myelination revisited

21 January 2018

1 reference

12 December 2020

Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase

1 reference

12 December 2020

Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer's disease.

1 reference

12 December 2020

Β-site APP-cleaving enzyme 1 trafficking and Alzheimer's disease pathogenesis

1 reference

12 December 2020

10.1007/S40266-013-0099-3

Identifiers

DOI

1 reference

29 August 2017

1 reference